Study identifier:1033IL/0027
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomised, Double-Blind, Double Dummy Trial To Compare The Efficacy And Safety Of ARIMIDEX (ZD1033 1MG Daily) With TAMOXIFEN (20MG Daily) As First Line Therapy For Advanced Breast Cancer In Postmenopausal Women.
Breast Cancer
Phase 3
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|